Lucid Capital initiated coverage of Cybin (CYBN) with a Buy rating and $106 price target Cybin is developing alternative formulations and derivatives of psychedelic drugs, the analyst tells investors in a research note. The firm points out the Drug Enforcement Agency classifies both of Cybin’s drugs as Schedule I, meaning “drugs with no currently accepted medical use and high potential for abuse.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Psychedelic: atai, Beckly Psytech to combine in all-share transaction
- Cybin Secures U.S. Patent for CYB004 Program in Anxiety Disorder Treatment
- Cybin announces additional U.S. patent supporting CYB004
- Cybin CEO to Discuss Strategic Advances at Upcoming Fireside Chat
- Cybin Supports FDA’s Push for Psychedelic Research